Several angiogenesis pathways are abnormally activated in HCC to support tumor development, including pathways involving vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor and their receptors, as well as pathways involving angiopoetin and Tie [4]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.